Question

Merită oare terapia cu celule stem pentru Insuficiență Ovariană Prematură?

For women with POI seeking fertility restoration, cell therapy offers a potentially tissue-regenerative alternative to indefinite hormone replacement and donor-egg IVF. The evidence is preliminary but growing; success rates are modest and highly variable. For women primarily concerned with symptom relief (hot flushes, vaginal dryness), conventional hormone replacement is simpler and better-established. Treatment at a reputable academic or trial centre (not an unregulated private clinic) reduces risk.

How stem cells are studied for Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI)—formerly called premature ovarian failure—is cessation of ovarian hormone production and egg release before age 40, affecting approximately 1 in 100 women. Causes include genetic mutations (e.g., FMR1), autoimmune attack on follicles, chemotherapy or radiation damage, infection, or idiopathic (unknown) depletion of the primordial follicle pool. The result is infertility, oestrogen deficiency, and systemic menopausal symptoms despite young age. Current treatment is hormone replacement; fertility restoration is limited. Placental MSCs and fetal stem cells are being explored to regenerate follicle development or restore ovarian hormone production through direct cellular replacement, growth-factor secretion, and immunomodulation (suppressing anti-ovarian autoimmunity). Transplantation of cells into the ovary or systemic infusion aims to stimulate dormant follicles or create a regenerative microenvironment.

Sunt un candidat? → · Premature Ovarian Insufficiency: full overview → · Cost Insuficiență Ovariană Prematură → · Cost →

Revizuit medical de echipa editorială a StemCellAtlas cu Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.

Terapie celulară de nivel european, fără prețuri europene.

Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.

Evaluare medicală gratuită